<DOC>
	<DOCNO>NCT00694941</DOCNO>
	<brief_summary>The objective study investigate long term safety ALS patient take ONO-2506PO .</brief_summary>
	<brief_title>A Phase II Multi-centre , Extension Study Investigate Long Term Safety ONO-2506PO Patients Diagnosed With Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>This extension study consist two phase : Double-blind phase ; Patients continue take blind study medication , allocate study ONO-2506POE014 central randomization system , presence stable standard Riluzole therapy , un-blinding study result . Open label phase ; Patients allocate ONO-2506PO ONO-2506POE014 study offer entry open label phase ONO-2506POE015 study continue take 1200 mg ONO-2506PO duration participation study , presence stable standard Riluzole therapy . Patients allocate placebo ONO-2506POE014 study withdraw ONO-2506POE015 study , continue follow site standard care .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Adult male female patient diagnosis ALS age 18 year . Previous randomization completion last visit ONO2506POE014 study . Patients investigator concern judge tolerable continued treatment ONO2506PO Riluzole risk benefit point view . A clinically relevant medical history presence cardiovascular , gastrointestinal , renal , hepatic , endocrine/metabolic , neurologic , lymphatic , haematologic , immunologic , musculoskeletal , connective tissue , dermatologic , genito/urinary , psychiatric disease disorder , opinion investigator may pose unwarranted risk patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>ONO-2506PO</keyword>
	<keyword>Amyotrophic Lateral Sclerosis</keyword>
	<keyword>ALS</keyword>
</DOC>